Breast and gynecologic diseases: from community pathogenetic views to practical sol

Authors

  • В. Е. Радзинский Russian Peoples’ Friendship University, Moscow, Russian Federation
  • И. М. Ордиянц Russian Peoples’ Friendship University, Moscow, Russian Federation
  • М. Н. Масленникова Moscow City Clinical Hospital № 12, Russian Federation
  • Е. А. Павлова Russian Peoples’ Friendship University, Moscow, Russian Federation

DOI:

https://doi.org/10.18370/2309-4117.2014.16.72-80

Keywords:

diffuse benign breast dysplasia, uterine fibroids, herbal medicine, Mastodynon

Abstract

Conservative treatment within rehabilitation program can improve the quality of life in 46-52% of patients with concomitant diseases of mammary glands and genitals, reduce the number of relapses and progression of diffuse benign breast dysplasia in patients with uterine cancer from 44% to 13-18%. This tactic helps eliminate a hormonal imbalance, improving the breast status (by ultrasound data).

Since no significant differences in the effectiveness of hormonal and herbal rehabilitation have been identified, the choice of a particular drug should depend on the clinical situation. Effectiveness of the preparation based on Agnus castus Mastodynon in the study was comparable to hormonal agents in terms of improving the quality of life and prevention of progression of benign breast diseases. 

Author Biographies

В. Е. Радзинский, Russian Peoples’ Friendship University, Moscow

MD, Professor, Head of the Obstetrics and Gynecology with Perinatology Course Department

И. М. Ордиянц, Russian Peoples’ Friendship University, Moscow

MD, Professor, of the Obstetrics and Gynecology with Perinatology Course Department

М. Н. Масленникова, Moscow City Clinical Hospital № 12

PhD, resident ph

Е. А. Павлова, Russian Peoples’ Friendship University, Moscow

graduate student of the Obstetrics and Gynecology with Perinatology Course Department

References

  1. Kulakov, VI. Manukhin, IB. Savelyev, GM. Gynecology: national leadership. M.: GEOTAR Media (2007).
  2. Suturina, LV. Popov, LN. «Effect of bromocriptine and Cyclodynone on clinical symptoms and prolactin levels of reproductive age with hyperprolactinemia.» Questions of gynecology, obstetrics and perinatology, 9 (2) (2010): 41-43
  3. Mustafin, CK. «Actual aspects of the treatment of diffuse mastopathy.» Attending Doctor, 10 (2008): 18-24.
  4. Radzinsky, VE. Breast and gynecological diseases. Moscow, (2010): 304.
  5. Letyagin, VP. Vysotskaya, IV. «Treatment of diffuse fibrocystic disease.» Tumors of the female reproductive system, 1-2 (2007): 47-49.
  6. Khaskhanov, LH. «Forecasting, early diagnosis and treatment of non-cancerous breast disease after surgical treatment of gynecological diseases.» Moscow, (2003): 47.
  7. Konovalov, VN. «Discussion Questions of tactics of women with benign breast diseases.» Effective pharmacotherapy in obstetrics and gynecology, 6 (2009): 6-12.
  8. Aleev, IA. «Are obstetricians treat breast disease? Joint discussion of problems.» Status Praesens, 4 (2012): 70-76.
  9. Cramer, D.W. Knapp, R.C. «Review of epidemiologic studies of endometrial cancer and exogenous estrogen.» Obstet. Gynecol, 54(4) (1979): 521-526.
  10. Kiselev, VI. Sidorov, IS. Hunanian, AL. Muyzhnek, EL. «Hyperplastic processes of the female reproductive system: theory and practice.» M.: Medical Practice-M, (2010): 468.
  11. Caruso-Nicoletti, M. et al. Ital. J. Ped., – 2003. 29 (2003): 110-113.
  12. Bublikov, ID. Kulikov, EP. Varenov, BM. «Hormonal status in patients with mastopathy.» Oncology Problems, T. 46 (2) (2000): 172-174.
  13. Prilepskaya, VN. Tagieva, TT. «Fibrocystic disease of the breast: opportunities of nonhormonal therapy.» Medline Express, 5 (2008): 10-17.
  14. Mansel, R.E. Webster, D.J.T. Sweetland, H.M. «Breast pain and nodularity.» Benign disorders and diseases of the breast. Elsevier,(2009): 107-139.
  15. Filippov, OS. «Benign breast diseases.» M.: MED press, (2008): 112.
  16. Radzinsky, VE. «Medicinal plants in obstetrics and gynecology.» 8th ed., Rev. and add., M.: Kanz- Exmo, (2008): 317.
  17. Rozhkov, NI. Mesquite, EV. «Mastodynon: possible use in various forms of mastitis.» Tumors of the female reproductive system, 4 (2008): 46-47.
  18. Choi, LK. «Drug therapy of diffuse mastopathy and ICP. Effective pharmacotherapy.» Oncology, hematology, and radiology, 3 (2010): 2-7.
  19. Daniele, C. Coon, J.T. Vitex agnus castus: A systematic review of adverse events.» Drug Safety, 28 (4) (2005): 331.
  20. Вуттке В., Ярри Г., Зайдлова-Вуттке Д. и др. Терапевтические возможности экстрактов из авраамова дерева (Vitex аgnus castus) в гинекологической практике // Пробл. репродукц. – 2009. – № 4. – С. 53–58.
  21. Smetnik, VP. Butareva, LB. «Experience of using phytodrug Cyclodynone (Agnucaston) in patients with insufficiency of the corpus luteum and hyperprolactinemia.» Problems of reproduction, 5 (2005): 1-4.
  22. Halaska, M. Beles, P. Gorkow, C. Sieder, C. «Treatment of cyclical mastalgia with a solution containing a Vitex agnus castus extract: results of a placebo-controlled double-blind study.» Breast, 8(4) (1999): 175-181. Aug.
  23. Kilicdag, E.B. Tarim, E. Bagis, T. Erkanli, S. Aslan, E. Ozsahin, K. Kuscu, E. «Fructus agni casti and bromocriptine for treatment of hyperprolactinemia and mastalgia.» Int J Gynaecol Obstet, 85 (3) (2004): 292-293. Jun
  24. Rozhkovа, NI. Mesquite, EV. «Vitex agnus castus use at various forms of mastitis.» Status Praesens, 1 (7) (2012): 39-43.

Downloads

Published

2014-07-11

How to Cite

Радзинский, В. Е., Ордиянц, И. М., Масленникова, М. Н., & Павлова, Е. А. (2014). Breast and gynecologic diseases: from community pathogenetic views to practical sol. REPRODUCTIVE ENDOCRINOLOGY, (16), 72–80. https://doi.org/10.18370/2309-4117.2014.16.72-80

Issue

No. 16 (2014)

Section

Gynecology

License

Copyright (c) 2014 В. Е. Радзинский, И. М. Ордиянц, М. Н. Масленникова, Е. А. Павлова

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

    1. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.